JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Medicine

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published: October 20th, 2016

DOI:

10.3791/54541

1Centre for Translational Omics, Genetics and Genomic Medicine Deptartment, Great Ormond Street Institute of Child Health, University College London, 2Dementia Research Centre, Institute of Neurology, University College London, 3Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, 4Neurology Unit, Department of Pathophysiology and Transplantation, University of Milan, 5Great Ormond Street Hospital for Children, University College London
* These authors contributed equally

We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.

Many neurodegenerative diseases are still lacking effective treatments. Reliable biomarkers for identifying and classifying these diseases will be important in the development of future novel therapies. Often potential new biomarkers do not make it into the clinic due to limitations in their development and high costs. However, targeted proteomics using Multiple Reaction Monitoring Liquid Chromatography-tandem/Mass Spectrometry (MRM LC-MS/MS), specifically using triple quadrupole mass spectrometers, is one method that can be used to rapidly evaluate and validate biomarkers for clinical translation into diagnostic laboratories. Traditionally, this platform has been used extensively for measurement of small molecules in clinical laboratories, but it is the potential to analyze proteins, that makes it an attractive alternative to ELISA (Enzyme-Linked Immunosorbent Assay)-based methods. We describe here how targeted proteomics can be used to measure multiplexed markers of dementia, including the detection and quantitation of the known risk factor apolipoprotein E isoform 4 (ApoE4).

In order to make the assay suitable for translation, it is designed to be rapid, simple, highly specific and cost effective. To achieve this, every step in the development of the assay must be optimized for the individual proteins and tissues they are analyzed in. This method describes a typical workflow including various tips and tricks to developing a targeted proteomics MRM LC-MS/MS for translation.

The method development is optimized using custom synthesized versions of tryptic quantotypic peptides, which calibrate the MS for detection and then spiked into CSF to determine correct identification of the endogenous peptide in the chromatographic separation prior to analysis in the MS. To achieve absolute quantitation, stable isotope-labeled internal standard versions of the peptides with short amino acid sequence tags and containing a trypsin cleavage site, are included in the assay.

The growing impact of neurodegenerative diseases such as Alzheimer's Disease, Lewy Body Dementia and Parkinson's Disease, is becoming a socioeconomic issue in many countries1. There is a need in additional biomarkers that can be used to identify and classify patients in the early stages of the disease, and to monitor any potential new treatments. The overall goal of this method is to create a generic pipeline for a streamlined, economic and faster way of validating potential CSF markers of neurodegeneration. The rationale is to use targeted proteomics or peptide MRM LC-MS/MS as an easily amendable method to assess multiple potential protei....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

NOTE: A schematic of the overall protocol described here is given in Figure 1. All samples used for the development of this method are surplus clinical diagnostic samples and have ethical approval from the London Bloomsbury Ethics committee.

Figure 1
Figure 1. Schematic Illustrating the Overall Process of Creating a Targeted CSF MRM LC-MS/MS Assay........

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Using the method described above, a high throughput 10 min multiplex assay consisting of 74 peptides from 54 proteins was developed, as an assay for markers of the neurodegenerative disorders Alzheimer's Disease and Lewy Body Dementia (LBD)8. Figure 3 shows a multiplex chromatogram published previously8 of the significant peptide markers from the assay. The peptides included in the assay and their quantitative transitions are given in Tab.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

As with all MS based assays, the critical steps in the method are the determination of the appropriate and accurate amounts of internal standards. If absolute quantitation is being used, then the correct amounts of spiked peptides in the standard curve are also critical.

Our assay does not require the precipitation of the CSF or the use of any type of clean up or desalting steps prior to MS analysis - it is an entirely one-pot reaction method. Due to the small volume of CSF and its limite.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This work was funded and facilitated through the GOSomics research initiative by the National Institute for Health Research, Biomedical Research Centre at Great Ormond Street Hospital and the UCL Biological Mass Spectrometry Centre at the UCL Institute of Child Health with kind donations from the Szeban Peto Foundation. The Dementia Research Centre is an Alzheimer's Research UK coordinating centre. The authors acknowledge the support of Alzheimer's Research UK, the NIHR Queen Square Dementia Biomedical Research Unit, UCL/H Biomedical Research Centre, and Leonard Wolfson Experimental Neurology Centre.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Name Company Catalog Number Comments
Acetonitrile (ACN), LC-MS grade  Fisher A955-1
Formic acid, LC-MS grade, Fisher A117-50
Dithiothreitol (DTT) Sigma  D5545-5G
Hydrochloric acid, 37% w/w VWR  BDH3028-2.5LG
Iodoacetamide   Sigma  I1149-5G
Sodium hydroxide (NaOH) Fisher S318-500
Trypsin, sequencing grade, modified Promega V5113
Trifluoroacetic acid (TFA), LC-MS grade Fisher A116-50
Urea Sigma U0631-500g
Water, LC-MS ULTRA Chromasolv Fluka 14263
Custom synthesised peptides desalted 1-4mg Genscript custom
heavy labelled amino acid [C13 N15] custom peptides Genscript custom
ASB 14 Merck Millipore 182750-25gm
Thiourea Sigma T7875-500G
Tris base Sigma T6066
VanGuard precolumn Waters 186007125
Cortecs UPLC C18+ 1.6um  2.1 x50mm column Waters 186007114
Yeast Enolase  Sigma E6126
300ul clear screw top glass vials   Fisher scientific 03-FISV
Y slit screw caps  Fisher scientific 9SCK-(B)-ST1X
Freeze dryer Edwards Mudulyo  Mudulyo system
Concentrator/Speed vaccum Eppendof  concentrator  plus 5301
Xevo -TQ-S mass spectrometer Waters
Acquity UPLC system Waters

  1. Prince, P. M., Guerchet, D. M., Prina, D. M., et al. . Policy Brief: The Global Impact of Dementia 2013-2050. , (2013).
  2. Hirtz, C., et al. Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clin Chim Acta. 454, 33-38 (2015).
  3. Marx, V. Targeted proteomics. Nat Methods. 10 (1), 19-22 (2013).
  4. Heywood, W., et al. The development of a peptide SRM-based tandem mass spectrometry assay for prenatal screening of Down syndrome. J Proteomics. 75 (11), 3248-3257 (2012).
  5. Heywood, W. E., et al. Proteomic Discovery and Development of a Multiplexed Targeted MRM-LC-MS/MS Assay for Urine Biomarkers of Extracellular Matrix Disruption in Mucopolysaccharidoses I, II, and VI. Anal Chem. , (2015).
  6. Manwaring, V., et al. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. J Proteome Res. 12 (5), 2013-2021 (2013).
  7. Moat, S. J., et al. Newborn blood spot screening for sickle cell disease by using tandem mass spectrometry: implementation of a protocol to identify only the disease states of sickle cell disease. Clin Chem. 60 (2), 373-380 (2014).
  8. Heywood, W. E., et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 10, 64 (2015).
  9. MacLean, B., et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26 (7), 966-968 (2010).
  10. Manes, N. P., Mann, J. M., Nita-Lazar, A. Selected Reaction Monitoring Mass Spectrometry for Absolute Protein Quantification. J Vis Exp. (102), e52959 (2015).
  11. Craig-Schapiro, R., et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 68 (10), 903-912 (2010).
  12. Perrin, R. J., et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 6 (1), e16032 (2011).
  13. Liguori, C., et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 71 (12), 1498-1505 (2014).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved